tricision key facts
- Developer of research and product and production technology platform designed for messenger ribonucleic acid (mRNA) nucleic acid drugs.
- Notable investors include CICC Capital, Yixing Jieyi Private Equity Fund Management, Guangzhou Financial Holdings, Kangtai Health, Sunshine Ronghui Capital Investment Management.
- Status: Privately Held (backing).
- ·Watch tricision: the Monday email on marks, rounds and moves
tricision funding rounds
No funding rounds for tricision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
tricision investors
5 investors are on record for tricision, including CICC Capital, Yixing Jieyi Private Equity Fund Management, Guangzhou Financial Holdings and Kangtai Health.
About tricision
Developer of research and product and production technology platform designed for messenger ribonucleic acid (mRNA) nucleic acid drugs. The company's technologies provide solutions for the prevention and treatment of cancer, infectious diseases, autoimmune diseases, genetic diseases, and more, enabling researchers and medical professionals to protect human health and life.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 100
- Website
- tricisionbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
tricision doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.